Kyverna Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewsWire • 03/26/26
Kyverna Therapeutics, Inc. (KYTX) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/13/26
Kyverna Therapeutics to Present New Data from Neuroimmunology Franchise at AAN 2026GlobeNewsWire • 03/05/26
Kyverna Therapeutics Appoints Biotech Leaders Sravan Emany and Andrew Miller to Board of DirectorsGlobeNewsWire • 02/24/26
Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/12/26
Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare ConferenceGlobeNewsWire • 01/05/26
Kyverna Therapeutics, Inc. (KYTX) Discusses Positive Topline Data From KYSA-8 Trial of Miv-cel in Stiff Person Syndrome TranscriptSeeking Alpha • 12/17/25
Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common StockGlobeNewsWire • 12/17/25
Kyverna Therapeutics: "Strong Buy" Rating As Positive SPS Data Leads To 1st Half 2026 BLA FilingSeeking Alpha • 12/16/25
KYTX Stock Rallies 23% on Upbeat Stiff Person Syndrome Study DataZacks Investment Research • 12/16/25
5 High-Risk, High-Reward Biotech Breakthrough Stocks to Watch in 2026Zacks Investment Research • 12/16/25
Lightwave Logic, Kyverna Therapeutics And Other Big Stocks Moving Lower In Tuesday's Pre-Market SessionBenzinga • 12/16/25
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person SyndromeSeeking Alpha • 12/15/25
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person SyndromeGlobeNewsWire • 12/15/25
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person SyndromeGlobeNewsWire • 12/14/25
Kyverna Therapeutics: Immune Reset Is Clinically Validated, Market Ignores PotentialSeeking Alpha • 11/14/25